Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Share:
Related ARIA
Watch These 10 Huge Put Purchases In Tuesday Trade
Benzinga's Option Alert Recap From January 30

In a report published Monday, Jefferies & Company reiterated its Buy rating on Ariad Pharmaceuticals (NASDAQ: ARIA), but lowered its price target from $27.00 to $23.00.

Jefferies & Company noted, “FDA approves Iclusig in CML/Ph+ ALL pts resistant/intolerant to TKIs, ~3 months earlier (PDUFA date of 3/27/13). Boxed warning on previously undisclosed safety issues (potential liver toxicity, arterial thrombosis) is surprising, although it's hard to know whether these are due to Iclusig, underlying disease, or both given single-arm PACE trial (& 1st-line EPIC interim data comparing ponatinib to imatinib expected ~1H14).”

Ariad Pharmaceuticals closed on Friday at $18.93.

Latest Ratings for ARIA

DateFirmActionFromTo
Jan 2017SunTrust Robinson HumphreyDowngradesBuyHold
Jan 2017JefferiesDowngradesBuyHold
Jan 2017BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

View Comments and Join the Discussion!